The novel time-limited combinations with the bcl-2 inhibitor venetoclax can induce deep responses even in CLL cases with unusual and biologically aggressive presentations, like the skin masses of our patient.
Keywords: CLL/SLL; MRD negativity; skin nodules; time‐limited treatment; venetoclax.
© 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.